Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour. Despite the absence of well controlled trials, bevacizumab is widely used in the treatment of recurrent glioblastoma. Nonetheless, whether the high response rates reported after treatment with this drug translate into an overall survival benefit remains unclear. We report the results of the first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Aug 2014

Volume: 15

Issue: 9

Affiliations

[1 ] Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

[2 ] Department of Medical Oncology, Medical Center Haaglanden, The Hague, Netherlands.

[3 ] Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands.

[4 ] Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

[5 ] Department of Oncology, St Elisabeth Ziekenhuis, Tilburg, Netherlands.

[6 ] Department of Neurology, Catharina Hospital Eindhoven, Netherlands.

[7 ] Department of Oncology, VU University Medical Center, Amsterdam, Netherlands.

[8 ] Department of Internal Medicine, Isala Kliniek, Zwolle, Netherlands.

[9 ] Department of Neurology, Rijnstate, Arnhem, Netherlands.

[10 ] Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.

[11 ] Department of Neurology, University Medical Center Groningen, Groningen, Netherlands.

[12 ] Department of Neurology, Medical Center Haaglanden, The Hague, Netherlands.

[13 ] Department of Oncology, Atrium MC Parkstad, Heerlen, Netherlands.

[14 ] Department of Oncology, Maastricht Universitair Medisch Centrum, Netherlands.

[15 ] Department of Neuro-oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

[16 ] Clinical Trial Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

[17 ] Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.

Article

Publisher Item ID: S1470-2045(14)70314-6

DOI: 10.1016/S1470-2045(14)70314-6

PubMed ID: 25035291

SO-VID: 78e44090-9534-4b03-a083-4e310ac73a83

History

Data availability:

Comments

Comment on this article

scite_

Cited by 259

See all cited by